Today's Date: June 4, 2023
Cupshe Celebrates 8th Birthday with Exclusive Collection in Collaboration with Chanel Iman, Heather Rae El Moussa, and Brittany   •   Reigniting the Cancer Moonshot: Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in C   •   Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipili   •   Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023   •   Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Developme   •   Government of Canada releases summary of actions taken to address the safety and wellbeing of Indigenous women, girls and 2SLGBT   •   Bijou Ikli named new CEO by Florida Assisted Living Association   •   Statement by the Prime Minister on Canadian Armed Forces Day   •   Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclit   •   Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam   •   New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Pl   •   TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years   •   High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy   •   GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting   •   Tips for a smooth transition to senior living from the San Luis Obispo assisted living professionals   •   Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different P   •   Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin   •   Dorsett Wanchai Marks World Environment Day 2023 with Bold Paperless and Plastic-Free Sustainability Initiatives
Bookmark and Share

Ankyra Therapeutics Appoints Experienced Financial Executive Stephen Gorgol as Chief Financial Officer

BOSTON , March 21 /Businesswire/ - Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced the appointment of Stephen Gorgol as chief financial officer. Mr. Gorgol, a proven financial leader within the biotech industry, joins Ankyra from Replimune Inc., where he served as chief accounting officer.

“We are thrilled to welcome Steve to the Ankyra team at this pivotal point in our development as we prepare to transition our lead candidate, ANK-101, into the clinic” said Howard L. Kaufman, M.D., president and chief executive officer of Ankyra. “Steve brings extensive financial and accounting biotech experience to the role, and his expertise will provide a valuable resource as we advance the company toward becoming a clinical-stage organization.”

“Ankyra has significant potential to transform cancer care for many patients in need, and I’m excited to join the company at this exciting time,” said Mr. Gorgol. He added, that “with our unique Anchored Immunotherapy Platform, we have the potential to deliver the beneficial aspects of cytokine therapeutics to patients, while avoiding the unwanted side effects. This platform, and our lead program, could offer tremendous value to both patients and our stakeholders, and I am pleased to partner with Howard and the team to advance them forward.”

Mr. Gorgol brings over 40 years of experience in financial-focused roles across several industries, including nearly 25 years in life sciences and biotechnology. He joins Ankyra from Replimune, where he served as the chief accounting officer and was responsible for financial, accounting, tax and human resources functions, and played a key role in the company’s successful 2018 initial public offering. Before Replimune, he served as vice president, finance and administration at uniQure. Prior to that, he served as the chief financial officer for BioVex, and earlier, as chief financial officer of Vista Medical Technologies. Before entering the biotechnology industry, he held a number of controller-focused roles. Mr. Gorgol received his B.S. in accounting from Plymouth State College in New Hampshire.

About Ankyra Therapeutics

Ankyra Therapeutics is a biotechnology company developing a novel approach to treating cancer, designed to expand the therapeutic window of cytokine drugs. Cytokine treatments have shown to be effective in treating cancer, but systemic dosing is limited by broad immune activation and toxicity. Using its proprietary Anchored Immunotherapy Platform, Ankyra has developed methods to localize cytokines specifically and persistently in tumor tissue, creating intense hot spots of inflammation that awaken an anti-tumor immune response. Using its platform, the company is building a pipeline of therapeutics designed to provide prolonged immune activation and potent local and systemic immunity with reduced systemic toxicity. For more information, please visit

STORY TAGS: Massachusetts, Biotechnology, Pharmaceutical, Health, Oncology, Personnel, United States, North America,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News